Previous Article | Next Article 
Molecular and Cellular Biology, May 2001, p. 3336-3342, Vol. 21, No. 10
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.10.3336-3342.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Hypoxia Extends the Life Span of Vascular Smooth
Muscle Cells through Telomerase Activation
T.
Minamino,
S. A.
Mitsialis, and
S.
Kourembanas*
Department of Medicine, Division of Newborn
Medicine, Children's Hospital, and Department of Pediatrics,
Harvard Medical School, Boston, Massachusetts 02115
Received 8 August 2000/Returned for modification 2 October
2000/Accepted 26 February 2001
 |
ABSTRACT |
Chronic hypoxia induces smooth muscle cell proliferation and vessel
wall remodeling in the vasculature of the lung. One well-characterized component of the hypoxic response is transcriptional activation of
genes encoding vascular smooth muscle cell (VSMC) mitogens. We report
here that chronic hypoxia can also prolong the growth of human VSMC by
inducing telomerase activity and telomere stabilization. We demonstrate
that hypoxia induced phosphorylation of the telomerase catalytic
component (TERT) and sustained high levels of TERT protein expression
in VSMC compared to normoxia. Furthermore, inhibition of telomerase
shortened cell life span in hypoxic cultures, whereas constitutive
expression of TERT extended the life span of cells under normoxic
conditions. Our data indicate that hypoxic induction of telomerase
activity could be involved in long-term growth of VSMC and may thus
contribute to human vascular disorders.
 |
INTRODUCTION |
Hypoxia is an important regulator of
physiologic processes, including erythropoiesis, angiogenesis, and
glycolysis (6). In the vasculature, chronic hypoxia has
been shown to cause proliferation of vascular smooth muscle cells
(VSMC), leading to vessel wall remodeling, a key pathophysiologic
component of pulmonary hypertension (11). The mechanisms
by which hypoxia regulates VSMC growth include direct cell
cycle-specific effects, as well as indirect effects, via the regulation
of VSMC mitogen production by endothelial cells (10).
Hypoxia triggers a cellular adaptive response that is primarily
mediated by the transcription factor hypoxia-inducible factor 1 (HIF-1)
(20). Expression of HIF-1 target genes serves to maintain
cellular homeostasis. Transcriptional activation of hypoxia-responsive
genes represents one major component of the vascular cell hypoxic
response; however, the mechanisms regulating long-term VSMC
proliferation in the vessel wall under chronic hypoxia remain to be elucidated.
Telomere integrity is essential for chromosome stability
(5) and therefore plays a crucial role in long-term cell
proliferation. Telomere length is maintained by telomerase, a
ribonucleoprotein that uses its associated RNA moiety as a template to
add telomeric repeats onto chromosome ends. High levels of telomerase
activity are readily detected in cancer cells but not in most normal
somatic cells, indicating that telomerase function is required for
tumor growth (9). Recent studies indicate that telomerase
activity is also present in highly proliferative somatic cell types,
such as activated lymphocytes (7). Moreover, in
later generations of mice lacking telomerase RNA, there is
decreased cell proliferation in highly proliferative organs
(12), suggesting that telomerase activity may also be
required for proliferation and long-term viability in these cells.
The mammalian telomerase RNA component (TERC) has been
identified, and its expression was shown to correlate with cell
proliferation as well as with telomerase activity in cancer cells
(3). Recently, two protein components have been isolated,
the mammalian homologue of the Tetrahymena RNA binding
protein p80 (TEP1) (19) and the mammalian homologue of the
yeast EST2 protein (TERT) (16). TERT mRNA levels were
reported to correlate with telomerase activity and to be implicated in
the regulation of telomerase activity in cancer cells
(16). Furthermore, telomerase activity in
telomerase-negative cells can be restored by ectopic expression of
TERT, suggesting that in certain cases, TERT is the only limiting
factor for telomerase activation (1).
We report here that primary VSMC express high levels of telomerase
activity when exposed to hypoxia and demonstrate a causal role of
telomerase activation in long-term growth of VSMC under chronic
hypoxia. Hypoxia significantly induced the phosphorylation of TERT
protein, resulting in increased telomerase activity and prolongation of
cell life span. TERT protein levels remained elevated under hypoxia
compared to those found under normoxia for significantly longer
population doublings (PD). Moreover, constitutive overexpression of
TERT prolonged VSMC life span under normoxia. These findings suggest
that hypoxia, a well-known regulator of vascular tone and wall
structure, not only regulates gene expression but also regulates cell
growth and survival via modulating telomerase activation in VSMC.
 |
MATERIALS AND METHODS |
Cell culture.
Primary cultures of rat aortic VSMC were grown
in Dulbecco's modified Eagle's medium (DMEM; GIBCO, Grand Island,
N.Y.) with 10% fetal calf serum and were used between passages 5 and
10. Primary cultures of human aortic VSMC were purchased from
BioWhittaker (Walkersville, Md.) and were cultured according to the
manufacturer's instructions. A7r5 rat fetal VSMC were obtained from
the American Type Culture Collection and were cultured in DMEM with
10% fetal calf serum. Media were changed every 3 days. Exposure of
cells to hypoxia (1% oxygen) was performed as described previously
(17). Human VSMC were cultured under normoxia (21%
oxygen) and hypoxia, and the media and gas were exchanged every 3 to 4 days. Whenever the culture became nearly confluent, the cells were
trypsinized, counted using trypan blue exclusion, and subcultured at a
density of 3,500 cells/cm2. The cultures were
terminated and regarded as senescent when the cell population did not
increase in 2 weeks. The senescent phenotype was confirmed by
-galactosidase activity assay as previously described
(22). PD were calculated as follows: PD = log (number of cells obtained/initial number of cells)/log 2. For inhibition of
telomerase, the cells were cultured in the presence of
3,3'-diethyloxadicarbocyanine (Calbiochem, San Diego, Calif.) or the
hexameric telomere-mimic TTAGGG phosphorothioate
oligonucleotides (Calbiochem).
Preparation of cell extracts.
Cytoplasmic S-100 extracts
were prepared as described previously except for the use of 0.5%
3-[-(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate (CHAPS) in place of
n-nonanoyl-N-methylglucamide
(21). Cell nuclei were isolated by centrifugation
(3,000 × g) after homogenization of the cells in
hypotonic buffer (10 mM HEPES [pH 8], 10 mM KCl, 0.1 mM EGTA, 1 mM
dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride [PMSF], 1 µg
of leupeptin/µl, 1 µg of aprotinin/µl, and 0.2% Nonidet P-40).
The nuclear pellets were resuspended in high-salt buffer (20 mM HEPES
[pH 8], 400 mM NaCl, 1 mM EGTA, 1 mM dithiothreitol, 0.5 mM PMSF, 1 µg of leupeptin/µl, 1 µg of aprotinin/µl, 10% glycerol) and
were rocked for 30 min at 4°C, and nuclear extracts were obtained by
centrifugation (15,000 × g).
Telomerase activity measurement.
Telomerase activity was
assayed by two methods: stretch PCR (21) and modified
telomeric repeat amplification protocol (TRAP; Oncor, Gaithersburg,
Md.) assays. Briefly, in the stretch PCR assay, 20 µl of a 2×
reaction mix (100 mM Tris-HCl [pH 8.5], 1 mM dATP, 1 mM TTP, 1 mM
dGTP, 10 mM
-mercaptoethanol, 2 mM EGTA, 0.1 mg of bovine serum
albumin/ml, 2 mM spermidine, 0.2 mM spermine, 20 pmol of forward primer
5'-GTA AAA CGA CGG CCA GTT TGG GGT TGG GGT TGG GGT TG-3')
was added to 20 µl of S-100 extracts, followed by incubation at
30°C for 60 min. The reaction was terminated by heat inactivation
(90°C, 1 min), and the mixture was treated with 0.15 mg of proteinase
K/ml at 37°C for 15 min. DNA products were isolated by
phenol-chloroform extraction and were then ethanol precipitated with
ammonium acetate. The precipitated DNA was dissolved in 39 µl of PCR
buffer (20 mM Tris-HCl [pH 8.3], 75 mM KCl, 1.5 mM
MgCl2, 0.005% Tween 20) with 5 pmol of reverse
primer 5'-CAG GAA ACA GCT ATG ACC CCT AAC CCT AAC CCT AAC
CCT-3'. Eleven microliters of a Taq mix (10 µl of
PCR buffer, 0.3 µl of 5-U/µl Taq polymerase [Boehringer
Mannheim]), 0.2 µl of dNTP mix (10 mM concentrations of dATP, TTP,
and dGTP and 1 mM dCTP), and 0.5 µl (3,000 Ci) of [
-32P]dCTP/mmol were added to the mixture,
which was preheated at 95°C, and then a PCR (93°C, 1 min; 68°C, 1 min; 72°C, 2 min for 25 cycles) was performed. PCR products were
analyzed on 7 M urea-7% polyacrylamide sequencing gel. The TRAP assay
was performed according to the manufacturer's instructions. Telomerase
activity was visualized by the characteristic 6-bp ladder and was
represented as the intensity of the entire ladder. We performed pilot
experiments using serially diluted samples and determined the linear
range of the assay. All analyses for telomerase activity were carried
out within this range. The specificity of telomerase products was
determined by their sensitivity to preincubation with RNase for each
sample. Telomerase products were quantified using a PhosphorImager
analyzer (Molecular Dynamics, Sunnywale, Calif.).
Introduction of TERT-FLAG in A7r5 cells.
The expression
vector, pcDNA3 TERT-FLAG, was the kind gift of F. Ishikawa (Department
of Life Science, Tokyo Institute of Technology, Tokyo, Japan).
Transfection of A7r5 cells was performed by Fugene (Boehringer
Mannheim, Indianapolis, Ind.) according to the manufacturer's
instructions. Transfected cells were grown in the presence of 1 mg of
G418/ml, and approximately 30 G418-resistant cell lines were isolated.
All clones were maintained in 250 µg of G418/ml.
Constitutive expression of TERT in human VSMC.
A cDNA
encoding human TERT, obtained by PCR cloning using pcDNA3 TERT-FLAG as
a template, was cloned into a pLNCX retroviral vector (Clontech, Palo
Alto, Calif.). Retroviral stocks were generated by transient
transfection of the packaging cell line (PT67; Clontech) and were
stored at
80°C until use. Human VSMC (passages 5 to 8) were plated
at 5 × 105 per 100-mm-diameter dish 24 h before infections. For infections, the culture medium was replaced
with retroviral stocks supplemented with 8 µg of Polybrene
(Sigma)/ml, and the cells were incubated at 37°C for 18 h.
Forty-eight hours after infections, the infected-cell populations were
selected by culture in 1 mg of G418/ml for 7 days. Cells infected with
empty vector (pLNCX) were used as the control.
Southern blot analysis.
Genomic DNA extracted by standard
methods was digested with HinfI and RsaI and was
resolved in 0.5% agarose gels. The blot was then hybridized with
32P-labeled (CCCTAA)3
at 42oC overnight to detect telomeric DNA,
washed under highly stringent conditions with 0.1× SSC-0.1% sodium
dodecyl sulfate (SDS) (1× SSC is 0.15 M NaCl plus 0.015 M sodium
citrate) and analyzed with a PhosphorImager (Molecular Dynamics). The
mean length of telomere restriction fragments was calculated by
converting the intensity of signals to molecular size based on DNA
molecular size markers using the formula L = (ODI)/(ODI /LI), where
ODI is the integrated signal at position I and
LI is the length of the DNA fragment in position I.
Western blot analysis.
Whole-cell lysates or nuclear
extracts were resolved by SDS-6% polyacrylamide gel electrophoresis
(PAGE). Proteins were transferred onto a polyvinylidene difluoride
(PVDF) membrane (Millipore, Bedford, Mass.) and incubated with
anti-TERT antibody (Calbiochem) or anti-FLAG antibody M2 (Sigma)
followed by an anti-rabbit immunoglobulin G-horseradish peroxidase
antibody or anti-mouse immunoglobulin G-horseradish peroxidase
antibody (Jackson, West Grove, Pa.). Specific proteins were detected
using enhanced chemiluminescence (Amersham, Piscataway, N.J.).
In vitro kinase reaction.
S-100 extracts (10 µg) in kinase
buffer (50 mM HEPES [pH 7.4], 10 mM MgCl2) were
incubated at 30°C in the presence or absence of 10 mM ATP for a time
as indicated. In some reactions, the protein kinase inhibitors
herbimycin A, tyrphostin A25, H7, myristoylated protein kinase A (PKA)
inhibitory peptide 14-22, myristoylated PKC inhibitory peptide 651-658, PKG inhibitory peptide 29-35, and PD98059 (Calbiochem) were also added
to the reaction mixture. The reactions were carried out in 10 µl, and
half of each mixture was analyzed for telomerase activity.
In vitro labeling of TERT.
For detection of phosphorylated
TERT in vitro, S-100 extracts (100 µg) in 50 µl of the reaction
mixture (50 mM HEPES [pH 7.4], 10 mM MgCl2, 1 mM ATP, and 1 µCi of [
-32P]ATP/µl) were
incubated for the indicated time intervals. After the reaction was
terminated by EDTA, the reaction mixtures were diluted by NP-40 buffer
(10 mM Tris-HCl [pH 8], 150 mM NaCl, 1% Nonidet P-40, 0.5 mM PMSF, 1 µg of leupeptin/µl, 1 µg of aprotinin/µl, 50 mM sodium
fluoride, 0.2 mM sodium vanadate, 10 U of RNase inhibitor/ml) and were
precleared by incubation with 50 µl of protein G-Sepharose (Pierce,
Rockford, Ill.). Anti-FLAG antibody was added to precleared samples and
incubated for 2 h. Protein G-Sepharose was then added to the
samples, which were incubated for an additional 2 h. The immunoprecipitates were washed four times with NP-40 buffer and resuspended in SDS sample buffer, and SDS-6% PAGE analysis was performed.
Orthophosphate labeling.
To detect phosphorylated TERT,
cultures were preincubated in labeling medium (phosphate-free DMEM) for
60 min. Then cells were incubated in the labeling medium containing 0.5 mCi of [32P]orthophosphate/ml for 6 h
under normoxia (21%) or hypoxia (1%) in the presence or absence of
H7. After incubation, whole-cell extracts were prepared and subjected
to immunoprecipitation with anti-FLAG antibody as described above,
except that radioimmunoprecipitation assay buffer (10 mM Tris-HCl [pH
8], 140 mM NaCl, 5 mM EDTA, 0.025% NaN3, 1%
Triton X-100, 1% deoxycholate, 0.1% SDS, 50 mM sodium fluoride, 0.2 mM sodium vanadate, 0.5 mM PMSF, 1 mg of leupeptin/ml, and 1 mg of aprotinin/ml) was used instead of NP-40 buffer. The immunoprecipitates were then resolved by SDS-6% PAGE and transferred onto a PVDF membrane followed by autoradiography and immunoblotting.
 |
RESULTS |
Chronic hypoxia extends replicative life span of human
VSMC.
We examined the effects of chronic hypoxia on long-term
growth and survival of VSMC in culture. Human primary VSMC were
cultured under normoxia (21% oxygen) or hypoxia (1% oxygen), and the
medium and gas were exchanged every 3 to 4 days. Whenever the culture became nearly confluent, the cells were trypsinized, counted, and
subcultivated. As shown in Fig. 1A,
chronic hypoxia significantly extended the life span of human VSMC
compared to that of normoxic cultures. Similar results were obtained
with VSMC from four different donors (two representative results are
shown in Fig. 1A, donors 1 and 2). Under hypoxic conditions, VSMC
continued to proliferate and maintained the morphology of early passage
cells (Fig. 1B, upper panel), whereas normoxic cultures adopted a flat,
enlarged shape and ceased proliferation at subconfluent densities, thus manifesting characteristics of senescence (Fig. 1B, lower panel). The
cytochemical senescent phenotype was also examined by use of
senescence-associated
-galactosidase (SA
-Gal) activity, which
has been shown to be a marker of senescence in vascular cells
(22) as well as in fibroblasts. Almost all normoxic
cultures revealed SA
-Gal activity, while only a few cells were
stained in hypoxic cultures at multiple comparable PD (Fig. 1C; data
not shown).

View larger version (56K):
[in this window]
[in a new window]
|
FIG. 1.
Hypoxia prolongs the life span of human VSMC. (A) VSMC
life span under normoxia and hypoxia. Primary cultures of human VSMC
were passaged under normoxia (21%) or hypoxia (1%) for the indicated
number of days, and PD since the onset of the experiment were
calculated as described in Materials and Methods. Results with cells
derived from two different donors (donors 1 and 2) are shown. Similar
results were obtained with cells from four different donors. (B) VSMC
morphology at late passages. Cultures propagated under hypoxia retained
a morphology characteristic of early passage VSMC (PD 38), whereas
normoxic cultures adopted a flat, enlarged shape (PD 33). Both cultures
shown here were derived from the same donor. Magnification, ×40. (C)
SA -Gal activity. SA -Gal staining was performed on normoxic
cultures at PD 33. Magnification, ×40.
|
|
Hypoxia induces telomerase activity.
To ascertain whether
proliferating VSMC express telomerase activity, cell extracts prepared
from subconfluent, primary, cultured rat, and cultured human VSMC were
assayed using either the stretch PCR or the TRAP technique. Significant
telomerase activity was detected in VSMC cultured under standard
conditions (Fig. 2A, normoxia). The level
of telomerase activity decreased as cultures approached confluency and
was greatly reduced upon serum deprivation of confluent cells,
suggesting a correlation of active telomerase with VSMC proliferation
(results not shown). VSMC telomerase activity was significantly induced
by hypoxia in cultured VSMC as early as 6 h after exposure of
cultures to 1% O2 (Fig. 2A, hypoxia).

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 2.
Hypoxia induces telomerase activity. (A) Induction of
telomerase activity by hypoxia in VSMC. Subconfluent human VSMC were
exposed to normoxia (21%) or hypoxia (1%), and S-100 extracts (10 µg) were analyzed for telomerase activity by the TRAP assay as
described in Materials and Methods. Telomerase activity is represented
by the characteristic 6-bp ladder and is proportional to the intensity
of the entire ladder. The specificity of the TRAP assay is validated by
sensitivity to preincubation of the extracts with RNase A. A fourfold
induction of telomerase activity was detected at 6 h of hypoxic
exposure. Similar results were observed in three independent
experiments using either stretch PCR or the TRAP assay. , absence of
RNase; +, presence of RNase. (B) TRF analysis. Genomic DNA (2 µg),
isolated from VSMC passaged under normoxia (21%) or hypoxia (1%) for
the indicated PD, was digested with HinfI and
RsaI and resolved in 0.5% agarose gels. The resultant
Southern blot was probed with 32P-labeled
(CCCTAA)3 as described in Materials and Methods.
(C) Quantitation of mean TRF length in normoxic (21%) and hypoxic
(1%) cultures. Length is given in kilobases. Similar results were
observed in cultures of VSMC from three different donors.
|
|
To ascertain whether telomerase induction by hypoxia affects telomere
length, we assayed for terminal restriction fragment (TRF) length by
Southern blotting. In contrast to progressive telomere shortening
observed in normoxic cultures, telomere length was preserved in hypoxic
cultures (Fig. 2B and C), consistent with sustained telomerase
activation under hypoxia. Similar preservation of telomere length and
of telomerase activity was observed in hypoxic cultures derived from
three donors (data not shown).
Inhibition of telomerase activity shortens cell life span of
hypoxic cultures.
To determine whether activation of telomerase
was responsible for prolonging VSMC life span in hypoxic cultures, we
inhibited telomerase activity using the telomerase inhibitors
3,3'-diethyloxadicarbocyanine (DODC) and telomere-mimic
oligonucleotides (TAG). DODC has previously been shown to bind
selectively to single DNA strands rich in guanine, resulting in
telomerase inhibition (4). TAG are hexameric, telomere-mimic phosphorothioate oligonucleotides (TTAGGG)
that have been shown to suppress telomerase activity (15,
23). Both agents effectively suppressed telomerase activity in
human VSMC in the range of 0.1 to 1 µM (data not shown) and
significantly shortened the cell life span of hypoxic cultures (Fig.
3A, compare 1% with TAG or DODC).
Hypoxic cultures treated with TAG or DODC exhibited a significantly
accelerated rate of telomere shortening compared to untreated controls
at the corresponding time point (day 62) (Fig. 3B, lanes 3, 4, and 6)
or number of PD (Fig. 3B, PD 31, lanes 2 and 4). Control
phosphorothioate oligonucleotides (TGTGAG) did not affect
telomere length (Fig. 3B, CONT). There was no significant cell death in
the cultures treated with control, DODC, or TAG at the concentrations
used; VSMC underwent growth arrest and manifested typical senescent
morphology, and the expression levels of the three telomerase
components were unaffected (data not shown). Thus, our data indicate
that the extension of VSMC life span conferred by hypoxia requires
elevated telomerase activity and can be reversed by accelerated rates
of telomere shortening.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 3.
Effects of telomerase inhibition on cell life span under
hypoxia. (A) Telomerase inhibitors prevent the hypoxia-induced
prolongation of VSMC life span. Human VSMC were passaged under normoxia
(21%) or hypoxia in the absence of telomerase inhibitors (1%) or
hypoxia in the presence of DODC (0.1 µM) or of TAG (1 µM). PD
values were calculated as described in Materials and Methods. (B)
Progressive telomere shortening by telomerase inhibition. Genomic DNA
(2 µg), which was extracted from VSMC passaged under hypoxia in the
absence of telomerase inhibitors (lanes 1 to 3) or in the presence of
DODC (lane 4), of control oligonucleotides (lane 5), or of
telomere-mimic oligonucleotides (TAG, lane 6) for the indicated number
of days, was analyzed for TRF length by Southern blotting as shown in
Fig. 2. Length is given in kilobases. The number of PD since the onset
of the experiment for each culture is also indicated.
|
|
Constitutive expression of TERT prolongs the growth of human
VSMC.
To prove a causal role for telomerase expression in
long-term VSMC growth, we constitutively overexpressed TERT in human
VSMC. Primary VSMC cultures were infected with a retroviral vector
expressing the TERT open reading frame, and several clones were
isolated. After cloning, the replicative life span of TERT-transfected
clones was examined and compared with that of mock-transfected clones. The time point when transfected clones were propagated to confluency in
a 100-mm-diameter dish was designated day 0 (approximately 20 to 30 PD
after infection). Mock-transfected clones ceased proliferating at 3 to
5 PD after cloning, whereas TERT-overexpressing lines showed a longer
life span and are still proliferating to date (Fig.
4A). TERT lines revealed high levels of
telomerase activity, whereas no telomerase activity was detected in
mock-transfected cells after cloning (Fig. 4B). Consistent with high
levels of telomerase activity in TERT lines, telomere length was
maintained after extensive passaging (data not shown). The morphology
of TERT lines after extensive passage remained similar to that of early
passage cell populations (Fig. 4C, upper photograph), while mock-transfected clones revealed the typical morphology of senescence after cloning (Fig. 4C, lower photograph). Similar observations were
obtained from all four lines that we examined and from pooled populations of TERT-overexpressing VSMC. Furthermore, TERT lines expressed markers of VSMC, such as smooth muscle light-chain kinase, and retained normal growth control in response to serum deprivation and
high cell density (data not shown). Thus, constitutive expression of
TERT greatly extended the life span of human VSMC but did not appear to
induce a transformed phenotype.

View larger version (58K):
[in this window]
[in a new window]
|
FIG. 4.
Overexpression of TERT extends the life span of human
VSMC. (A) Replicative life span of TERT-overexpressing VSMC lines.
Human VSMC were infected with a retroviral vector encoding TERT or the
empty vector (Mock), and infected clones were isolated and expanded.
The time point when isolated lines had been propagated to near
confluency in a 100-mm-diameter dish was designated day 0 (approximately 20 to 30 PD after infection). Cultures were subsequently
passaged under normoxia for the indicated time, and PD were calculated
as for Fig. 1. Similar results were obtained from four independently
isolated lines as well as from pooled populations. (B) Telomerase
activity in TERT-infected VSMC lines. S-100 extracts (0.1 µg) were
prepared from TERT- or mock-infected clones at day 0 and were analyzed
by TRAP assay as described for panel A. , absence of RNase; +,
presence of RNase; ITAS, internal telomerase assay standard. (C)
Morphology of TERT-overexpressing lines. After extensive passage,
TERT-expressing lines manifested a morphology similar to that of early
passage VSMC (upper photograph), while mock-infected lines revealed the
typical morphology of senescence (lower photograph).
|
|
Protein phosphorylation of TERT contributes to telomerase
activation.
Telomerase activity was significantly higher in VSMC
cultured under hypoxia than under normoxia at any PD value and
decreased in hypoxia only at very high PD values (Fig.
5A). We noted that levels of the
telomerase RNA component and TEP1 were not altered in our
long-term hypoxic cell culture model as determined by reverse transcriptase PCR (data not shown). By contrast, sustained high expression of TERT protein was observed in hypoxic cultures for a
significantly longer period and higher PD than in normoxic cultures (Fig. 5B, upper panel for nuclear extracts and middle panel for whole-cell extracts). TERT protein was significantly reduced earlier in
normoxic cells (Fig. 5B, PD 32) and considerably later in hypoxic cells
(Fig. 5B, PD 44 and 46). However, there was no strict quantitative relationship between telomerase activity and TERT expression levels. For example, although telomerase activity in hypoxic cultures was 10 times as high as that in normoxic cultures at PD 21 (Fig. 5A), TERT
protein levels were similar at PD 21 under normoxia or hypoxia (Fig.
5B). In addition, short-term hypoxic exposure did not affect TERT
protein levels, whereas telomerase activity was induced by four- to
fivefold (Fig. 2A and data not shown). Therefore, in addition to TERT
expression levels, these findings imply the existence of additional
posttranslational mechanisms for the regulation of telomerase activity.

View larger version (65K):
[in this window]
[in a new window]
|
FIG. 5.
Protein phosphorylation contributes to telomerase
activation. (A) Telomerase activity in normoxic and hypoxic cultures.
S-100 extracts (10 µg) from cell populations of donor 1 under
normoxia (21%) and hypoxia (1%) at the indicated PD were assayed for
telomerase activity using the stretch PCR assay as described in
Materials and Methods. Similar results were obtained in cultures from
three different donors. (B) TERT levels under normoxia and hypoxia.
Nuclear extracts (15 µg, upper panel) or whole-cell lysates (50 µg,
middle panel), extracted from normoxic (21%) or hypoxic cultures (1%)
at the indicated PD, were analyzed by Western blotting using an
anti-TERT antibody. Nuclear extracts (20 µg) from HeLa cells were
used as a positive control. The same blot was reprobed with
anti- -actin antibody to verify equal loading among lanes (lower
panel). Similar results were obtained in VSMC from three different
donors. (C) Effects of protein kinase inhibitors on in vitro telomerase
activity. S-100 extracts (10 µg) prepared from serum-deprived rat
VSMC were incubated at 30°C for 10 min in the presence (+) or absence
( ) of 10 µM ATP, as indicated. Lanes 4 to 10 included the following
protein kinase inhibitors: herbimycin A (10 µM) (Her); tyrphostin A25
(100 µM) (Tyr); H7 (50 µM); PKA inhibitory peptide (1 µM); PKC
inhibitory peptide (50 µM); PKG inhibitory peptide (100 µM); and
PD98059 (50 µM) (PD). Lane 11 included 10 µM ATP S. After
incubation, reaction mixtures were assayed for telomerase activity
using the stretch PCR assay. Results shown are representative of three
similar experiments. Similar results were obtained in human VSMC. (D)
Phosphorylation of TERT in vitro. S-100 extracts (100 µg) prepared
from TERT-FLAG cells (lanes 1 to 4) and mock-transfected cells (lane 5)
that had been deprived of serum for 3 days were supplemented with 1 mM
ATP and 1 µCi of [ 32P]ATP/µl and were
immunoprecipitated with anti-FLAG antibody immediately (lane 1) or
after 10 h of incubation (lanes 2 to 5). H7 (10 mM) was present in
lane 3, and 20 µg of FLAG-competing peptide (Pep) was present in lane
4. Immunoprecipitates were then resolved by SDS-6% PAGE, and
phosphorylated TERT-FLAG was detected by autoradiography (upper gel).
One-tenth of each immunoprecipitate was also directly assayed for
telomerase activity using the stretch PCR assay (lower gel). ,
absence of RNase; +, presence of RNase. 0, 0 h; 10, 10 h.
|
|
Recent reports have implied sensitivity of telomerase activity to
protein phosphorylation (13). We hypothesized that the activation of telomerase by hypoxia may be mediated by such a mechanism. To test this hypothesis, we first examined the effects of
ATP on telomerase activity in vitro. Cell extracts prepared from rat
VSMC that had been deprived of serum for 7 days (a situation that
greatly suppresses telomerase activity) were incubated with ATP in the
presence of 10 mM MgCl2 and were then assayed for
telomerase activity. As shown in Fig. 5C, telomerase activity was
dramatically stimulated by 10 min of incubation with ATP prior to the
assay (Fig. 5C, lanes 2 and 3). adenosine-5'-
-thiotriphosphate
(ATP
S) did not induce telomerase activity (Fig. 5C, lane 11),
indicating that ATP hydrolysis is required for this activation. The
kinase inhibitors H7 (Fig. 5C, lane 6), PKC (Fig. 5C, lane 8), and to a
lesser degree, PKA inhibitory peptide (Fig. 5C, lane 7) prevented the
stimulation of telomerase activity, whereas the tyrosine kinase inhibitors herbimycin A (Fig. 5C, lane 4) and tyrphostin (Fig. 5C, lane
5) or the MAP kinase kinase (MEK) inhibitor PD98059 (Fig. 5C, lane 10)
had no significant effect. Similar results were observed in human VSMC
(data not shown). These findings suggest that protein phosphorylation,
in particular H7-sensitive kinase(s), mediates the stimulation of
telomerase activity by ATP in vitro.
More recently, phosphorylation of TERT has been shown to regulate
telomerase activity in cancer cells (14). Thus, we
speculated that phosphorylation of the TERT component may be
responsible for the activation of telomerase in VSMC. Rat fetal VSMC
(A7r5 line) were transfected with TERT-FLAG expression vector,
and lines which constitutively express TERT-FLAG protein were
established. Expression of TERT-FLAG protein was determined by Western
blotting using anti-FLAG antibody (data not shown). To determine
whether protein phosphorylation of TERT contributed to telomerase
activation, we prepared cell extracts from TERT-FLAG cells deprived of
serum for 3 days to suppress telomerase activity and created an in
vitro kinase reaction in the presence of 1 mM ATP and 1 µCi of
[
-32P]ATP/µl. In vitro kinase reaction
mixtures were then immunoprecipitated with anti-FLAG antibody.
One-tenth of the immunoprecipitates was also assayed for telomerase
activity. TERT-FLAG protein was strongly phosphorylated 10 min after
incubation with ATP and was associated with a stimulation of telomerase
activity (Fig. 5D, lane 2). Preincubation with FLAG peptide completely
abolished detection of TERT-FLAG as well as abolishing telomerase
activity in the immunoprecipitate (Fig. 5D, lane 4). In addition, no
TERT-specific band was detected in the reaction mixtures of
mock-transfected cells (Fig. 5D, lane 5), suggesting that the anti-FLAG
antibody specifically immunoprecipitated the telomerase complex. H7
inhibited both telomerase activity and the phosphorylation of TERT-FLAG
protein (Fig. 5D, lane 3), indicating that phosphorylation of TERT is
involved in stimulating telomerase activity.
We next sought to determine whether TERT protein is
phosphorylated in cells in response to hypoxia and whether
phosphorylation was required for telomerase activation. VSMC were
treated with H7 and exposed to hypoxia for 6 h. Treatment with H7
prevented the hypoxic induction of telomerase activity in both rat and
human VSMC cultures (Fig. 6A). We
therefore examined phosphorylated TERT levels in normoxic and hypoxic
cultures in the absence or presence of H7. VSMC transfected with
TERT-FLAG expression vector were labeled with
[32P]orthophosphate for 6 h under normoxia
or hypoxia, and TERT-FLAG protein was immunoprecipitated with
anti-FLAG antibody. Phosphorylated TERT was detected in both normoxic
and hypoxic cultures; however, phosphorylation was remarkably enhanced
by hypoxia (Fig. 6B, upper panel, lanes 1 and 2). Western blotting
confirmed comparable levels of immunoreactive TERT in the
immunoprecipitates (Fig. 6B, lower panel). Furthermore, treatment
of hypoxic cultures with H7 reduced levels of phosphorylated TERT (Fig.
6B, lane 3), suggesting that protein phoshorylation of TERT modulates
telomerase activity under hypoxia.

View larger version (50K):
[in this window]
[in a new window]
|
FIG. 6.
Phosphorylation of TERT protein in VSMC by hypoxia. (A)
Effect of protein kinase inhibitors on telomerase activity in cultured
cells in vivo under hypoxia. Human VSMC were cultured under normoxia
(left lane) or hypoxia for 6 h in the presence (right lane) or
absence (middle lane) of H7 (50 µM). After hypoxic exposure, S-100
extracts were prepared and incubated at 30°C for 10 min in the
presence of 10 µM ATP. Reaction mixtures were assayed for telomerase
activity using the stretch PCR assay. Results shown are representative
of three independent experiments and were similar between human and rat
VSMC. (B) Phosphorylation of TERT in vivo. VSMC transfected with TERT
FLAG expression vector were labeled with
[32P]orthophosphate for 6 h under normoxia (lane 1)
or hypoxia in the absence (lanes 1, 2, and 4) or the presence (lane 3)
of H7 (10 µM). TERT FLAG protein was immunoprecipitated with
anti-FLAG antibody in the absence (lanes 1 to 3) or the presence (lane
4) of FLAG-competing peptide. The immunoprecipitates were then
subjected to SDS-6% PAGE analysis and transferred onto a PVDF
membrane followed by autoradiography to detect phosphorylated TERT FLAG
(p-TERT FLAG) and by immunoblotting with anti-FLAG antibody to detect
immunoreactive TERT FLAG (ir-TERT FLAG).
|
|
 |
DISCUSSION |
Hypoxia regulates multiple physiologic and pathological processes
in the body. Many cardiopulmonary disorders are associated with hypoxia
and result in increased morbidity and mortality. Hypoxia has profound
effects on blood vessel tone and wall structure by regulating gene
expression and cell-cell interaction in vascular cells
(10). In the lung vasculature, chronic hypoxia leads to smooth muscle cell hyperplasia with medial hypertrophy of the pulmonary
arterioles and the clinical picture of pulmonary hypertension. These
VSMC proliferative changes have been attributed to the increased growth
factors released by endothelial cells in response to hypoxia. It has
previously been reported that VSMC have a hypoxic response independent
of endothelial cells. In VSMC, hypoxia stimulates the transcription of
heme oxygenase-1, the principal enzyme responsible for carbon monoxide
generation (18), as well as stimulating the expression of
E2F-1, a key cell cycle-specific transcription factor
(17). Thus, independently of endothelial cells, hypoxia modulates VSMC gene expression and cell cycle progression. In the
present report, we have demonstrated a causal role of telomerase activation and telomere function for the long-term growth and viability
of VSMC under conditions of hypoxia. First, we detected relatively high
levels of telomerase activity in VSMC that are not usually observed in
normal somatic cells. Second, chronic hypoxia extended the growth and
life span of human VSMC and was associated with telomere stabilization
as well as higher levels of telomerase activity. Third, the life span
of hypoxic human VSMC was effectively shortened by inhibition of
telomerase activity, while it was extended in normoxic cells by
constitutive expression of TERT. Combined, these data support a
physiologic role for telomerase activity in regulating VSMC
proliferation under hypoxic conditions.
Multiple adaptive responses to hypoxia involve transcriptional
activation of vascular cell gene expression. In the case of telomerase,
additional mechanisms control its activity in response to hypoxia. We
propose here mechanisms whereby telomerase is activated by hypoxia via
phosphorylation of TERT protein at least partly by a PKC-dependent
pathway. Consistent with this, the potent mitogenic response to hypoxia
has been reported to be partially mediated by PKC activation
(2). We observed that high levels of TERT protein were
sustained in long-term hypoxic cultures, while short-term hypoxia did
not change expression levels of TERT. The half-life of telomerase has
been shown to be relatively long (24 h) (8). Thus, it is
assumed that constitutive activation of telomerase by hypoxia is
regulated mainly by protein phosphorylation of TERT or potentially
other, additional posttranslational mechanisms.
Telomerase activity appeared to be related to cell proliferation in
VSMC; however, whether telomerase activity is necessary for short-term
proliferation of VSMC remains unclear. Recent studies using mice null
for the telomerase RNA component indicated that telomerase deficiency
per se did not affect short-term cell proliferation in embryonic
fibroblasts but did reduce long-term cell viability in proliferative
organs. Thus, it is likely that mitogenic stimuli, for instance
hypoxia, activate both telomerase and the cell cycle machinery,
allowing VSMC to continuously proliferate with minimal telomere
shortening. Consistent with this, hypoxic exposure was shown to promote
VSMC proliferation by increasing the expression of the cell cycle
transcription factor E2F-1 (17). Enhanced cell cycle
progression combined with telomere stabilization may be important in
highly proliferative pathological conditions in the vasculature that
are characterized by sustained and long-standing vessel wall remodeling.
In summary, we have shown a critical role for telomerase activity in
long-term growth and viability of VSMC in culture in response to
hypoxia. Hypoxia induced telomerase activity in VSMC by stimulating
TERT protein phosphorylation, resulting in telomere stabilization and
the maintenance of high expression levels of TERT. Telomerase
activation under chronic hypoxia may result in enhanced and sustained
VSMC proliferation and vessel wall remodeling, findings characteristic
of proliferative vascular disorders, such as pulmonary hypertension.
Further investigations on telomerase and telomere function on the
growth and long-term survival of VSMC would provide new insights into
the pathophysiology and treatment of human vasculopathies.
 |
ACKNOWLEDGMENTS |
This work was supported by the American Heart Association and by
National Institutes of Health grants RO1 HL55454 and SCOR 1P50 HL56398.
We thank F. Ishikawa for pcDNA3 TERT-FLAG and L. Lynch for expert
technical assistance. We also thank J. Johnson for her expert assistance in the preparation of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Division of
Newborn Medicine, Children's Hospital, Enders 9, 300 Longwood Ave.,
Boston, MA 02115. Phone: (617) 355-7383. Fax: (617) 355-7677. E-mail: Stella.Kourembanas{at}tch.harvard.edu.
Present address: Teikyo University Hospital, Chiba 0111, Japan.
 |
REFERENCES |
| 1.
|
Bodnar, A. G.,
M. Ouellette,
M. Frolkis,
S. E. Holt,
C.-P. Chiu,
G. B. Morin,
C. B. Harley,
J. W. Shay,
S. Lichtsteiner, and W. E. Wright.
1998.
Extension of life-span by introduction of telomerase into normal human cells.
Science
279:349-352[Abstract/Free Full Text].
|
| 2.
|
Dempsey, E. C.,
I. F. McMurtry, and R. F. O'Brien.
1991.
Protein kinase C activation allows pulmonary artery smooth muscle cells to proliferate to hypoxia.
Am. J. Physiol.
260:L136-L145[Abstract/Free Full Text].
|
| 3.
|
Feng, J.,
W. D. Funk,
S.-S. Wang,
S. L. Weinrich,
A. A. Avilion,
C.-P. Chiu,
R. R. Adams,
E. Chang,
R. C. Allsopp,
J. Yu,
S. Le,
M. D. West,
C. B. Harley,
W. H. Andrews,
C. W. Greider, and B. Villeponteau.
1995.
The RNA component of human telomerase.
Science
269:1236-1241[Abstract/Free Full Text].
|
| 4.
|
Fu, W.,
J. G. Begley,
M. W. Killen, and M. P. Mattson.
1999.
Anti-apoptotic role of telomerase in pheochromocytoma cells.
J. Biol. Chem.
274:7264-7271[Abstract/Free Full Text].
|
| 5.
|
Greider, C. W.
1996.
Telomere length regulation.
Annu. Rev. Biochem.
65:337-365[CrossRef][Medline].
|
| 6.
|
Guillemin, K., and M. A. Krasnow.
1997.
The hypoxic response: huffing and HIFing.
Cell
89:9-12[CrossRef][Medline].
|
| 7.
|
Hiyama, K.,
Y. Hirai,
S. Kyoizumi,
M. Akiyama,
E. Hiyama,
M. A. Piatyszek,
J. W. Shay,
S. Ishioka, and M. Yamakido.
1995.
Activation of telomerase in human lymphocytes and hematopoietic progenitor cells.
J. Immunol.
155:3711-3715[Abstract].
|
| 8.
|
Holt, S. E.,
W. E. Wright, and J. W. Shay.
1996.
Regulation of telomerase activity in immortal cell lines.
Mol. Cell. Biol.
16:2932-2939[Abstract].
|
| 9.
|
Kim, N. W.,
M. A. Piatyszek,
K. R. Prowse,
C. B. Harley,
M. D. West,
P. L. C. Ho,
G. M. Coviello,
W. E. Wright,
S. L. Weinrich, and J. W. Shay.
1994.
Specific association of human telomerase activity with immortal cells and cancer.
Science
266:2011-2015[Abstract/Free Full Text].
|
| 10.
|
Kourembanas, S.,
T. Morita,
H. Christou,
Y. Liu,
H. Koike,
D. Brodsky,
D. Arthur, and S. A. Mitsialis.
1998.
Hypoxic responses of vascular cells.
Chest
114:25S-28S[Free Full Text].
|
| 11.
|
Kourembanas, S.,
T. Morita,
Y. Liu, and H. Christou.
1997.
Mechanisms by which oxygen regulates gene expression and cell-cell interaction in the vasculature.
Kidney Int.
51:438-443[Medline].
|
| 12.
|
Lee, H.-W.,
M. A. Blasco,
G. J. Gottlieb,
J. W. I. Horner,
C. W. Greider, and R. A. DePinho.
1998.
Essential role of mouse telomerase in highly proliferative organs.
Nature
392:569-574[CrossRef][Medline].
|
| 13.
|
Li, H.,
L. L. Zhao,
J. W. Funder, and J.-P. Liu.
1997.
Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells.
J. Biol. Chem.
272:16729-16732[Abstract/Free Full Text].
|
| 14.
|
Li, H.,
L. Zhao,
Y. Zhiyong,
J. W. Funder, and J.-P. Liu.
1998.
Telomerase is controlled by protein kinase C in human breast cancer cells.
J. Biol. Chem.
273:33436-33442[Abstract/Free Full Text].
|
| 15.
|
Mata, J. E.,
S. S. Joshi,
B. Palen,
S. J. Pirruccello,
J. D. Jackson,
N. Elias,
T. J. Page,
K. L. Medlin, and P. L. Iversen.
1997.
A hexameric phosphorothioate oligonucleotide telomerase inhibitor arrests growth of Burkitt's lymphoma cells in vitro and in vivo.
Toxicol. Appl. Pharmacol.
144:189-197[CrossRef][Medline].
|
| 16.
|
Meyerson, M.,
C. M. Counter,
E. N. Eaton,
L. W. Ellisen,
P. Steiner,
S. D. Caddle,
L. Ziaugra,
R. L. Beijersbergen,
M. J. Davidoff,
Q. Liu,
S. Aacchetti,
D. A. Haber, and R. A. Weinberg.
1997.
hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization.
Cell
90:785-795[CrossRef][Medline].
|
| 17.
|
Morita, T.,
S. A. Mitsialis,
H. Koike,
Y. Liu, and S. Kourembanas.
1997.
Carbon monoxide controls the proliferation of hypoxic vascular smooth muscle cells.
J. Biol. Chem.
272:32804-32809[Abstract/Free Full Text].
|
| 18.
|
Morita, T.,
M. A. Perrella,
M.-E. Lee, and S. Kourembanas.
1995.
Smooth muscle cell-derived carbon monoxide is a regulator of vascular cGMP.
Proc. Natl. Acad. Sci. USA
92:1475-1479[Abstract/Free Full Text].
|
| 19.
|
Nakayama, J.-I.,
M. Saito,
H. Nakamura,
A. Matsuura, and F. Ishikawa.
1997.
TLP1: a gene encoding a protein component of mammalian telomerase is a novel member of WD repeats family.
Cell
88:875-884[CrossRef][Medline].
|
| 20.
|
Semenza, G. L.
1999.
Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1.
Annu. Rev. Cell Dev. Biol.
15:551-578[CrossRef][Medline].
|
| 21.
|
Tatematsu, K.-I.,
J.-I. Nakayama,
M. Danbara,
S. Shionoya,
H. Sato,
M. Omine, and F. Ishikawa.
1996.
A novel quantitative "stretch PCR assay" that detects a dramatic increase in telomerase activity during the progression of myeloid leukemias.
Oncogene
13:2265-2274[Medline].
|
| 22.
|
van der Loo, B.,
M. J. Fenton, and J. D. Erusalimsky.
1998.
Cytochemical detection of a senescence-associated -galactosidase in endothelial and smooth muscle cells from human and rabbit blood vessels.
Exp. Cell Res.
241:309-315[CrossRef][Medline].
|
| 23.
|
Zahler, A. M.,
J. R. Williamson,
T. R. Cech, and D. M. Prescott.
1991.
Inhibition of telomerase by G-quartet DNA structures.
Nature
350:718-720[CrossRef][Medline].
|
Molecular and Cellular Biology, May 2001, p. 3336-3342, Vol. 21, No. 10
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.10.3336-3342.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Ray, J. B., Arab, S., Deng, Y., Liu, P., Penn, L., Courtman, D. W., Ward, M. E.
(2008). Oxygen regulation of arterial smooth muscle cell proliferation and survival. Am. J. Physiol. Heart Circ. Physiol.
294: H839-H852
[Abstract]
[Full Text]
-
Herbert, K. E., Mistry, Y., Hastings, R., Poolman, T., Niklason, L., Williams, B.
(2008). Angiotensin II-Mediated Oxidative DNA Damage Accelerates Cellular Senescence in Cultured Human Vascular Smooth Muscle Cells via Telomere-Dependent and Independent Pathways. Circ. Res.
102: 201-208
[Abstract]
[Full Text]
-
Bell, E. L., Klimova, T. A., Eisenbart, J., Schumacker, P. T., Chandel, N. S.
(2007). Mitochondrial Reactive Oxygen Species Trigger Hypoxia-Inducible Factor-Dependent Extension of the Replicative Life Span during Hypoxia. Mol. Cell. Biol.
27: 5737-5745
[Abstract]
[Full Text]
-
Lou, F., Chen, X., Jalink, M., Zhu, Q., Ge, N., Zhao, S., Fang, X., Fan, Y., Bjorkholm, M., Liu, Z., Xu, D.
(2007). The Opposing Effect of Hypoxia-Inducible Factor-2{alpha} on Expression of Telomerase Reverse Transcriptase. Mol Cancer Res
5: 793-800
[Abstract]
[Full Text]
-
Minamino, T., Komuro, I.
(2007). Vascular Cell Senescence: Contribution to Atherosclerosis. Circ. Res.
100: 15-26
[Abstract]
[Full Text]
-
Fuster, J. J., Andres, V.
(2006). Telomere Biology and Cardiovascular Disease. Circ. Res.
99: 1167-1180
[Abstract]
[Full Text]
-
Matthews, C., Gorenne, I., Scott, S., Figg, N., Kirkpatrick, P., Ritchie, A., Goddard, M., Bennett, M.
(2006). Vascular Smooth Muscle Cells Undergo Telomere-Based Senescence in Human Atherosclerosis: Effects of Telomerase and Oxidative Stress. Circ. Res.
99: 156-164
[Abstract]
[Full Text]
-
Schissel, S. L., Layne, M. D.
(2006). Telomerase, myofibroblasts, and pulmonary fibrosis.. Am. J. Respir. Cell Mol. Bio.
34: 520-522
[Full Text]
-
Kunieda, T., Minamino, T., Katsuno, T., Tateno, K., Nishi, J.-i., Miyauchi, H., Orimo, M., Okada, S., Komuro, I.
(2006). Cellular Senescence Impairs Circadian Expression of Clock Genes In Vitro and In Vivo. Circ. Res.
98: 532-539
[Abstract]
[Full Text]
-
Ibe, B. O., Portugal, A. M., Chaturvedi, S., Raj, J. U.
(2005). Oxygen-dependent PAF receptor binding and intracellular signaling in ovine fetal pulmonary vascular smooth muscle. Am. J. Physiol. Lung Cell. Mol. Physiol.
288: L879-L886
[Abstract]
[Full Text]
-
Edo, M. D., Andres, V.
(2005). Aging, telomeres, and atherosclerosis. Cardiovasc Res
66: 213-221
[Abstract]
[Full Text]
-
Brusselmans, K., Bono, F., Collen, D., Herbert, J.-M., Carmeliet, P., Dewerchin, M.
(2005). A Novel Role for Vascular Endothelial Growth Factor as an Autocrine Survival Factor for Embryonic Stem Cells during Hypoxia. J. Biol. Chem.
280: 3493-3499
[Abstract]
[Full Text]
-
Matsuura, K., Wada, H., Nagai, T., Iijima, Y., Minamino, T., Sano, M., Akazawa, H., Molkentin, J. D., Kasanuki, H., Komuro, I.
(2004). Cardiomyocytes fuse with surrounding noncardiomyocytes and reenter the cell cycle. J. Cell Biol.
167: 351-363
[Abstract]
[Full Text]
-
Borras, C., Esteve, J. M., Vina, J. R., Sastre, J., Vina, J., Pallardo, F. V.
(2004). Glutathione Regulates Telomerase Activity in 3T3 Fibroblasts. J. Biol. Chem.
279: 34332-34335
[Abstract]
[Full Text]
-
Nishi, H., Nakada, T., Kyo, S., Inoue, M., Shay, J. W., Isaka, K.
(2004). Hypoxia-Inducible Factor 1 Mediates Upregulation of Telomerase (hTERT). Mol. Cell. Biol.
24: 6076-6083
[Abstract]
[Full Text]
-
Haendeler, J., Hoffmann, J., Diehl, J. F., Vasa, M., Spyridopoulos, I., Zeiher, A. M., Dimmeler, S.
(2004). Antioxidants Inhibit Nuclear Export of Telomerase Reverse Transcriptase and Delay Replicative Senescence of Endothelial Cells. Circ. Res.
94: 768-775
[Abstract]
[Full Text]
-
Serrano, A. L., Andres, V.
(2004). Telomeres and Cardiovascular Disease: Does Size Matter?. Circ. Res.
94: 575-584
[Abstract]
[Full Text]
-
Kang, H. J., Choi, Y. S., Hong, S.-B., Kim, K.-W., Woo, R.-S., Won, S. J., Kim, E. J., Jeon, H. K., Jo, S.-Y., Kim, T. K., Bachoo, R., Reynolds, I. J., Gwag, B. J., Lee, H.-W.
(2004). Ectopic Expression of the Catalytic Subunit of Telomerase Protects against Brain Injury Resulting from Ischemia and NMDA-Induced Neurotoxicity. J. Neurosci.
24: 1280-1287
[Abstract]
[Full Text]
-
Minamino, T., Yoshida, T., Tateno, K., Miyauchi, H., Zou, Y., Toko, H., Komuro, I.
(2003). Ras Induces Vascular Smooth Muscle Cell Senescence and Inflammation in Human Atherosclerosis. Circulation
108: 2264-2269
[Abstract]
[Full Text]
-
Yang, X., Sheares, K. K. K., Davie, N., Upton, P. D., Taylor, G. W., Horsley, J., Wharton, J., Morrell, N. W.
(2002). Hypoxic Induction of Cox-2 Regulates Proliferation of Human Pulmonary Artery Smooth Muscle Cells. Am. J. Respir. Cell Mol. Bio.
27: 688-696
[Abstract]
[Full Text]
-
Erusalimsky, J. D., Fenton, M., Minamino, T., Miyauchi, H., Yoshida, T., Komuro, I., Ishida, Y., Yoshida, H.
(2002). Further In Vivo Evidence That Cellular Senescence Is Implicated in Vascular Pathophysiology * Response. Circulation
106
: e144-e144
[Full Text]
-
Cong, Y.-S., Wright, W. E., Shay, J. W.
(2002). Human Telomerase and Its Regulation. Microbiol. Mol. Biol. Rev.
66: 407-425
[Abstract]
[Full Text]
-
Minamino, T., Kourembanas, S.
(2001). Mechanisms of Telomerase Induction During Vascular Smooth Muscle Cell Proliferation. Circ. Res.
89: 237-243
[Abstract]
[Full Text]
-
Minamino, T., Miyauchi, H., Yoshida, T., Ishida, Y., Yoshida, H., Komuro, I.
(2002). Endothelial Cell Senescence in Human Atherosclerosis: Role of Telomere in Endothelial Dysfunction. Circulation
105: 1541-1544
[Abstract]
[Full Text]